Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation & Amortization (CF) (2016 - 2025)

Cytokinetics (CYTK) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed N/A to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.1 million for FY2025, 6.23% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.0 million at Cytokinetics, up from $2.3 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $6.3 million in Q4 2023, with the low at $462000.0 in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.9 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 13.81% in 2021, then soared 282.09% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $734000.0 in 2021, then soared by 125.89% to $1.7 million in 2022, then skyrocketed by 282.09% to $6.3 million in 2023, then tumbled by 61.94% to $2.4 million in 2024, then rose by 23.48% to $3.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $3.0 million, $2.3 million, and $2.4 million for Q4 2025, Q1 2025, and Q3 2024 respectively.